论文部分内容阅读
本文对52例原发性肝癌（下称肝癌）进行血清甲胎蛋白（AFP）、α－L—岩藻糖苷酶（AFU）、CA19-9联合检测。结果表明，肝癌组与肝硬化组及正常对照组比较，其含量均有非常显著差异（P＜0．001）。肝癌组血清AFP、AFU、CA19-9单项检测及三项联合检测，其敏感性分别为63．5％、71．2％、61．5％及94.2％。血清AFP、AFU、CA19-9诊断肝癌的特异性分别为95．1％、87．8％、90．2％；准确性分别为77．4％、74．2％、75．2％。在19例AFP阴性的肝癌患者中血清AFU、CA19-9的敏感性分别为57.9％（11/19）、73.7％（14/19）。本文结果说明AFP、AFU、CA19-9三项联合检测可明显提高肝癌诊断的敏感性，可以避免漏诊，具有重要的临床意义。
In this paper, 52 cases of primary liver cancer (hereinafter referred to as hepatocellular carcinoma) were tested for combined serum alpha-fetoprotein (AFP), alpha-L-fucosidase (AFU), and CA19-9. The results showed that there was a significant difference in the content of the liver cancer group compared with the cirrhosis group and the normal control group (P<0.001). The sensitivity of serum AFP, AFU, CA19-9 single test and three combined tests in liver cancer group was 63.5%, 71.2%, 61.5% and 94.2%, respectively. The specificities of serum AFP, AFU, and CA19-9 in the diagnosis of liver cancer were 95.1%, 87.8%, and 90.2%, respectively; the accuracy was 77.4%, 74.2%, and 75.2%, respectively. The sensitivity of serum AFU and CA19-9 in 19 patients with AFP-negative liver cancer was 57.9% (11/19) and 73.7% (14/19), respectively. The results of this study show that the combined detection of AFP, AFU, and CA19-9 can significantly improve the sensitivity of liver cancer diagnosis and avoid missed diagnosis, which has important clinical significance.